FIRST EC LAUNCH OF ZOVIRAX
FIRST EC LAUNCH OF OTC ZOVIRAX
Wellcome has been granted approval by the German regulatory authorities to market an over-the-counter version of its best-selling antiviral product Zovirax (aciclovir). An OTC version of the drug has already been launched in New Zealand, but Germany represents the first European Community country to approve the drug. Wellcome has submitted for approval in a number of other EC states.
OTC Zovirax will be marketed for the treatment of cold sores blisters, caused by infection with Herpes simplex virus. Cold sores affect between 15% and 40% of the population, according to Wellcome, and this bodes well for an OTC version of the drug, because many people do not visit their doctor for the condition.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze